Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus

Mayo Clin Proc. 1986 Jun;61(6):442-7. doi: 10.1016/s0025-6196(12)61978-8.


Slowing starch digestion by inhibiting amylase activity in the intestinal lumen should improve postprandial carbohydrate tolerance in patients with diabetes mellitus. Crude bean-derived amylase inhibitor ("starch blocker") that contains only minimal antiamylase activity, however, does not modify carbohydrate assimilation. To test the validity of the "starch blockade" concept, we assessed the effect of a partially purified bean-derived amylase inhibitor with increased antiamylase activity on carbohydrate tolerance in normal subjects and in patients with non-insulin-dependent diabetes mellitus. In comparison with a placebo, ingestion of this inhibitor with 50 g of starch substantially reduced postprandial increases in plasma concentrations of glucose and insulin in both normal subjects and those with diabetes. We conclude that a purified amylase inhibitor is effective and potentially beneficial in the treatment of diabetes mellitus.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Amylases / antagonists & inhibitors*
  • Blood Glucose / analysis*
  • Breath Tests
  • C-Peptide / analysis
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / therapy
  • Dietary Carbohydrates / metabolism*
  • Female
  • Humans
  • Hydrogen / analysis
  • Insulin / blood
  • Intestinal Absorption
  • Lactulose / metabolism
  • Male
  • Middle Aged
  • Starch / metabolism


  • Blood Glucose
  • C-Peptide
  • Dietary Carbohydrates
  • Insulin
  • Lactulose
  • Hydrogen
  • Starch
  • Amylases